Anticoagulation therapy versus placebo for pulmonary hypertension

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 6, 2014, Pages

  Ezedunukwe, Ifeanyi R ^a   Enuh, Hilary ^b   Nfonoyim, Jay ^b   Enuh, Collins U ^c  

^a LAGOS UNIVERSITY TEACHING HOSPITAL   (Nigeria)

^b RICHMOND UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF ABUJA   (Nigeria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; PLACEBO;

ADVERSE EVENT; ANTICOAGULANT THERAPY; DRUG EFFICACY; HUMAN; INTERNATIONAL NORMALIZED RATIO; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; HYPERTENSION, PULMONARY;

ANTICOAGULANTS; HUMANS; HYPERTENSION, PULMONARY; INTERNATIONAL NORMALIZED RATIO; PLACEBOS;

EID: 84942739582     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD010695.pub2     Document Type: Review

References (47)

1. Akagi S, Kusano KF. Anticoagulation therapy in pulmonary arterial hypertension. Japanese Journal of Clinical Medicine Nippon Rinsho 2008;66(11):2174-8.
2. Bouvier CA, Ritschard J, Meykadeh F, Fournet P, Duchosal PW. Fibrinolytic therapy of severe pulmonary hypertension. Justification, modality and criticism [Traitement fibrinolytique de l'hypertension pulmonaire severe justification, molalites et critique]. Schweizerische medizinische Wochenschrift Journal Suisse de Medecine 1970;100(4):148-51.
3. Cohen M, Edwards WD, Fuster V. Regression in thromboembolic type of primary pulmonary hypertension during 2 1/2 years of antithrombotic therapy. Journal of the American College of Cardiology 1986;7(1):172-5.
4. Elder DH, Goudie JA, Szwejkowski A, Choy A, Struthers A, Lang CC. Warfarin use is associated with increased survival in patients with left ventricular systolic dysfunction and pulmonary hypertension. European Heart Journal Conference; 2012 25-28 Aug; Munchen. 2012:168-9.
5. Frank H, Mlczoch J, Huber K, Schuster E, Gurtner HP, Kneussl M. The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension. Chest 1997;112(3):714-21.
6. Fuster V, Steele PM, Edward WD, Gersh BJ, McGoon MD, Frye RL. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1984;70:580-7. [DOI: 10.1161/01.CIR.70.4.580]
7. Gomez-Arroyo JG, Sandoval J, Santos-Martinez LE, Rueda T, Miranda M, Roquet I. Oral anticoagulation therapy in children, adolescents and young adults with pulmonary arterial hypertension: a 10-year survival analysis. American Journal of Respiratory and Critical Care Medicine 2010;181:A3338.
8. Henkens IR, Hazenoot T, Boonstra A, Huisman MV, Vonk-Noordegraaf A. Major bleeding with vitamin K antagonist anticoagulants in pulmonary hypertension. European Respiratory Journal 2013;41(4):872-8. [DOI: 10.1183/09031936.00039212]
9. Jansa P, Hrachovinova I, Ambroz D, Maresova J, Polacek P, Simkova I, et al.Effect of warfarin anticoagulation on thrombin generation in patients with idiopathic pulmonary arterial hypertension. Bratislavske Lekarske Listy 2011;111(11):595-6.
10. Johnson SR, Mehta S, Granton JT. Anticoagulation in pulmonary arterial hypertension: a qualitative systematic review. European Respiratory Journal 2006;28:999-1004. [DOI: 10.1183/09031936.06.00015206]
11. Johnson S, Graton JT, Tomlinson G, Grosbein HA, Hawker GA, Feldman BM. Effect of warfarin on survival in scleroderma-associated pulmonary arterial hypertension (SSc-PAH) and idiopathic PAH. Belief elicitation for bayesian priors. Journal of Rheumatology 2011;38(3):462-9.
12. Johnson SR, Granton JT, Tomlinson GA, Grosbein HA, Le T, Lee P, et al.Warfarin in systemic sclerosis-associated and idiopathic pulmonary arterial hypertension. A Bayesian approach to evaluating treatment for uncommon disease. Journal of Rheumatology 2012;39(2):276-85.
13. Kawut S, Horn E, Berekashvili K, Garofano R, Goldsmith RL, Widlitz AC, et al.New predictors of outcome in idiopathic pulmonary arterial hypertension. American Journal of Cardiology 2005;95:199-203.
14. Ogata M, Ohe M, Shirato K, Takishima T. Effects of a combination therapy of anticoagulant and vasodilator on the long-term prognosis of primary pulmonary hypertension. Japanese Circulation Journal 1993;57(1):63-9.
15. Olsson KM, Delcroix M, Ghofrani HA, Tiede H, Huscher D, Speich R, et al.Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). Circulation 2014;129:57-65. [DOI: 10.1161/CIRCULATIONAHA.113.004526]
16. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium channel blockers on survival in primary pulmonary hypertension. New England Journal of Medicine 1992;327(2):76-81.
17. Romaszkiewicz R, Lewczuk J, Piszko P, Jagas J, Lenartowska L, Ludwik B, et al.Results of one-year anticoagulation in patients with newly detected chronic thromboembolic pulmonary hypertension not treated with pulmonary endarterectomy. Kardiologia Polska 2006;64(11):1196-202;discussion 1203-4.
18. Stortein O, Efskind L, Muller C, Rokseth R, Sander S. Primary pulmonary hypertension with emphasis on its etiology and treatment. Acta Medica Scandinavica 1966;179(2):197-212.
19. Badesch BD, Champion HC, Gomez-Sanchez MA, Hoeper M, Loyd J, Manes A, et al.Diagnosis and assessment of pulmonary arterial hypertension. Journal of the American College of Cardiology 2009;54:S55-6.
20. Barst RJ, Gibbs JS, Ghofrani HA, Hoeper MM, McLaughlin VV, Rubin LJ, et al.Updated evidence-based treatment algorithm in pulmonary arterial hypertension. Journal of the American College of Cardiology 2009;54(1 Suppl):S78.
21. Bedard E, Dimopoulos K, Gatzoulis MA. Has there been any progress made on pregnancy outcomes among women with pulmonary arterial hypertension?. European Heart Journal 2009;30:256-65.
22. Bjornsson J, Edwards WD. Primary pulmonary hypertension:a histopathologic study of 80 cases. Mayo Clinic Proceedings 1985;60:16-25.
23. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al.Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Annals of Internal Medicine 1991;115:343-9.
24. DiMarco JP, Flaker G, Waldo AL, Corley SD, Greene HL, Safford RE, et al.Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. American Heart Journal 2005;149:650-5.
25. Duchini A, Sessoms SL. Gastrointestinal hemorrhage in patients with systemic sclerosis and CREST syndrome. American Journal of Gastroenterology 1998;93:1453-6.
26. Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, et al.Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). ESC Committee for Practice Guidelines (CPG). European Heart Journal 2009;30(20):2493.
27. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org.
28. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, et al.Cellular and molecular pathobiology of pulmonary arterial hypertension. Journal of the American College of Cardiology 2004;43(12 Suppl S):13. [PUBMED: 15194174 ]
29. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, et al.Pulmonary arterial hypertension in France: results from a national registry. American Journal of Respiratory Care Medicine 2006;173(9):1023.
30. Johnson SR, Granton JT, Mehta S. Thrombotic arteriopathy and anticoagulation in pulmonary hypertension. Chest 2006;130:545-55.
31. Johnson SR, Granton JT, Tomlinson GA, Grosbein HA, Le T, Lee P, et al.Warfarin in systemic sclerosis-associated and idiopathic pulmonary arterial hypertension. A Bayesian approach to evaluating treatment for uncommon disease. Journal of Rheumatology 2012;39(2):276-85. [DOI: 10.3899/jrheum.110765]
32. Kovacs G, Berghold A, Scheidl S, Olschewski H. Pulmonary arterial pressure during rest and exercise in healthy subjects. A systematic review. European Respiratory Journal 2009;34(4):888-94. [DOI: 10.1183/09031936.00145608]
33. Ling Y, Johnson MK, Kiely DG, Condliffe R, Elliot CA, Gibbs JS, et al.Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland. American Journal of Respiratory Critical Care Medicine 2012;186(8):790.
34. Marcus JT, Gan CT, Zwanenburg JJ, Boonstra A, Allaart CP, Gotte MJW. Interventricular mechanical asynchrony in pulmonary arterial hypertension: left-to-right delay in peak shortening is related to right ventricular overload and left ventricular underfilling. Journal of the American College of Cardiology 2008;51:750-7.
35. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, et al.ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. ACCF/AHA Circulation 2009;119(16):2250.
36. Murphey LM, Hood EH. Bosentan and warfarin interaction. Annals of Pharmacotherapy 2003;37:1028-31.
37. Ogawa A, Matsubara H, Fujio H, Miyaji K, Nakamura K, Morita H, et al.Risk of alveolar hemorrhage in patients with primary pulmonary hypertension - anticoagulation and epoprostenol therapy. Circulation 2005;69:216-20.
38. Paulus WJ, Tschope C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE, et al.How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the heart failure and echocardiography. European Heart Journal 2007;28:2539-50.
39. Peacock AJ, Murphy NF, McMurray JJV, Caballero L, Stewart S. An epidemiological study of pulmonary arterial hypertension. European Respiratory Journal 2007;30:104-9.
40. Pietra GG, Capron F, Stewart S, Leone O, Humbert M, Robbins IM, et al.Pathologic assessment of vasculopathies in pulmonary hypertension. Journal of the American College of Cardiology 2004;43(12 Suppl S):25. [PUBMED: 15194175]
41. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
42. Rich S. Executive summary from the World Symposium on Primary Pulmonary Hypertension, Evian, France, co-sponsored by The World Health Organization. World Symposium on Primary Pulmonary Hypertension; 1998; Sep 6-10; Evian. 1998.
43. Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, et al.Updated clinical classification of pulmonary hypertension. Journal of the American College of Cardiology 2009;54:S43.
44. Thenappan T, Shah SJ, Rich S, Gomberg-Maitland M. A USA-based registry for pulmonary arterial hypertension: 1982-2006. European Respiratory Journal 2007;30(6):1103-10. [DOI: 10.1183/09031936.00042107]
45. Torbicki A. Cardiac magnetic resonance in pulmonary arterial hypertension: a step in the right direction. European Heart Journal 2007;28:1187-9.
46. Wagenvoort CA. Lung biopsy specimens in the evaluation of pulmonary vascular disease. Chest 1980;77:614-25.
47. Widlitz AC, Barst RJ, Horn EM. Sitaxsentan: a novel endothelin-A receptor antagonist for pulmonary arterial hypertension. Expert Review of Cardiovascular Therapy 2005;3:985-91.